Loading...
  • complications
  • Most common late complications and prevalence were chronic graft versus host disease (43% at 5 years post HSCT), secondary tumor (21% at 20 years post HSCT), hypothyroidism (11% at 15 years), bronchiolitis obliterans (9.7% at 122 days), cardiovascular disease (7.5% at 15 years) and avascular necrosis (5.4% at 10 years). (springer.com)
  • While allogenic stem cell transplantation is an effective cure for leukaemia, the procedure is associated with complications that can have their onset many years after the procedure. (springer.com)
  • multiple myeloma
  • Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma. (nih.gov)
  • Characterization and use of the novel human multiple myeloma cell line MC-B11/14 to study biological consequences of CRISPR-mediated loss of immunoglobulin A heavy chain. (amedeo.com)
  • Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. (nih.gov)
  • clinical
  • The objective of the Phase II, prospective, multi-center trial was to determine the feasibility and effectiveness of a uniform reduced intensity conditioning regimen prior to a blood cell transplant in older AML patients in clinical remission. (medicalxpress.com)
  • Clinical signs of CRS correlate with T-cell activation and high levels of cytokines, including interleukin 6 (IL-6). (medscape.com)
  • During this period of time, other changes in clinical practices could have affected the risks for IA, including the use of alternative stem cell sources and conditioning regimens. (bloodjournal.org)
  • My current clinical efforts and basic research focus on improving the safety and efficacy of hematopoietic cell transplantation (HCT) which is the most widely practiced and powerful form of cellular therapy. (stanford.edu)
  • In 2013, I chaired a taskforce to develop recommendations to decrease the length of time between protocol release and protocol activation at centers participating in the Bone Marrow Transplant Clinical Trials Network. (copays.org)
  • immune
  • Suppresses some humoral immunity and more so cell-mediated immune reactions. (medscape.com)
  • Low IL-2 Expressing T Cells in Thalassemia Major Patients: Is It Immune Aging. (ithanet.eu)
  • malignant cells
  • Because malignant cells persisted after HCT, treatment was administered with azacytidine, and immunosuppression with tacrolimus was withdrawn by day 100, 3 months earlier than originally planned. (bloodjournal.org)
  • Nevertheless, there are disadvantages of removing the T-cells, since they are important in fighting viral infections as well as any remaining malignant cells. (clinicaltrials.gov)